Mucosal innate immune pathways

Mucosal innate immune pathways constitute the primary defense mechanism at the body's barrier surfaces, such as the gastrointestinal, respiratory, and urogenital tracts (PubMed: 27173297). These pathways utilize pattern recognition receptors (PRRs), including Toll-like receptors (TLRs) and NOD-like receptors (NLRs), to detect pathogen-associated molecular patterns (PAMPs) and initiate rapid protective responses (PubMed: 27173297, NIH: PMC4159119). Upon activation, these pathways stimulate the production of antimicrobial peptides, mucus, and pro-inflammatory cytokines that recruit and activate other immune cells (ASM: 10.1128/IAI.00123-16). Dysregulation of these pathways is central to the pathogenesis of chronic inflammatory conditions like inflammatory bowel disease (IBD) and asthma, as well as susceptibility to mucosal infections (PubMed: 27173297, NIH: PMC4159119). Pharmacological intervention typically targets specific nodes within these pathways, such as TLRs or downstream cytokine signaling, to either enhance host defense or suppress pathological inflammation (PubMed: 27173297). Note: 'Mucosal innate immune pathways' refers to a broad biological category rather than a single molecular target.

Other names

Mucosal innate immunityInnate mucosal immune systemMucosal host defense pathwaysMucosal innate immune response

Drugs modulate mucosal innate immune pathways by agonizing or antagonizing pattern recognition receptors (e.g., TLRs), inhibiting downstream signaling kinases (e.g., JAKs), or neutralizing effector cytokines (e.g., TNF, IL-1, IL-23) and their receptors to regulate the inflammatory response at mucosal barriers (PubMed: 27173297, NIH: PMC4159119).